Helicobacter pylori World Gastroenterology Organization Global Guideline.

Helicobacter pylori remains a major health problem worldwide, causing considerable morbidity and mortality due to peptic ulcer disease and gastric cancer. The burden of disease falls disproportionally on less well-resourced populations. As with most infectious diseases, the largest impact on reducing this burden comes from improvement in socioeconomic status, which interrupts transmission. This has been observed in many regions of the world, but the prevalence of infection remains high in many regions where improvements in living standards are slow to occur. Meanwhile, the optimal clinical management and treatment pathways remain unsettled and are evolving with changing antimicrobial resistance patterns. Despite decades of research and clinical practice, major challenges remain. The quest for the most effective, safe, and simple therapy remains the major issue for clinicians. The search for an effective vaccine appears to be elusive still. Clinical guidelines do not infrequently proffer discordant advice. A major challenge for guidelines is for relevance across a variety of populations with a varying spectrum of disease, antimicrobial resistance rates, and vastly different resources. As local factors are central to determining the impact and management strategies for H. pylori infection, it is important that pathways are based on the best available local knowledge rather than solely extrapolating from guidelines formulated in other regions, which may be less applicable. To this end, this revision of the World Gastroenterology Organisation (WGO) H. pylori guideline uses a "Cascades" approach that seeks to summarize the principles of management and offer advice for pragmatic, relevant and achievable diagnostic and treatment pathways based on established key treatment principles and using local knowledge and available resources to guide regional practice.

De novo construction of T cell compartment in humanized mice engrafted with iPSC-derived thymus organoids.

Hematopoietic humanized (hu) mice are powerful tools for modeling the action of human immune system and are widely used for preclinical studies and drug discovery. However, generating a functional human T cell compartment in hu mice remains challenging, primarily due to the species-related differences between human and mouse thymus. While engrafting human fetal thymic tissues can support robust T cell development in hu mice, tissue scarcity and ethical concerns limit their wide use. Here, we describe the tissue engineering of human thymus organoids from inducible pluripotent stem cells (iPSC-thymus) that can support the de novo generation of a diverse population of functional human T cells. T cells of iPSC-thymus-engrafted hu mice could mediate both cellular and humoral immune responses, including mounting robust proinflammatory responses on T cell receptor engagement, inhibiting allogeneic tumor graft growth and facilitating efficient Ig class switching. Our findings indicate that hu mice engrafted with iPSC-thymus can serve as a new animal model to study human T cell-mediated immunity and accelerate the translation of findings from animal studies into the clinic.

Irritable bowel syndrome in celiac disease - relationships to celiac disease antibodies and levels of pro-inflammatory cytokines.

BACKGROUND: Evidence indicates that low-grade inflammation can alter gastrointestinal motor and sensory function and might contribute to the genesis of symptoms in IBS. OBJECTIVE: To examine relationships between IBS, disease antibodies and cytokine titers in celiac patients and a control group. MATERIALS AND METHODS: IBS, CD activity and serum levels of IL-6, IL-8 and IL12/23p40 were determined in celiac patients and controls. RESULTS: 123 celiac patients were included, 89% were female. 59% demonstrated disease activity and 32% met IBS criteria. Prevalence of IBS was not different between patients who adhered or did not adhere to GFD as well as between patients with or without positive antibodies. Celiac patients had increased levels of IL-6, IL-8 and IL12/23p40 as compared to controls. Higher levels of cytokines were found in celiac patients with IBS than in those without IBS. No difference in levels of cytokines was found between patients with and without CD positive antibodies. A significant negative correlation between the mental component of QoL and IL-6 and IL12/23p40 levels was found, but not with IL-8. CONCLUSION: Higher levels of inflammatory cytokines were found in CD patients with IBS than in either those without IBS or controls, indicating that IBS symptoms are associated with an increase in the inflammatory response and a decrease in quality of life of CD patients. These differences in cytokine levels were not related to CD antibodies status suggesting that IBS, in CD, is related to a different inflammatory process than that which is relevant to CD.

Irritable bowel syndrome in celiac disease - relationships to celiac disease antibodies and levels of pro-inflammatory cytokines / Síndrome del intestino irritable en la enfermedad celíaca: relaciones con los anticuerpos contra la enfermedad celíaca y los niveles de citocinas proinflamatorias

ABSTRACT Background: Evidence indicates that low-grade inflammation can alter gastrointestinal motor and sensory function and might contribute to the genesis of symptoms in IBS. Objective: To examine relationships between IBS, disease antibodies and cytokine titers in celiac patients and a control group. Materials and methods: IBS, CD activity and serum levels of IL-6, IL-8 and IL12/23p40 were determined in celiac patients and controls. Results: 123 celiac patients were included, 89% were female. 59% demonstrated disease activity and 32% met IBS criteria. Prevalence of IBS was not different between patients who adhered or did not adhere to GFD as well as between patients with or without positive antibodies. Celiac patients had increased levels of IL-6, IL-8 and IL12/23p40 as compared to controls. Higher levels of cytokines were found in celiac patients with IBS than in those without IBS. No difference in levels of cytokines was found between patients with and without CD positive antibodies. A significant negative correlation between the mental component of QoL and IL-6 and IL12/23p40 levels was found, but not with IL-8. Conclusion: Higher levels of inflammatory cytokines were found in CD patients with IBS than in either those without IBS or controls, indicating that IBS symptoms are associated with an increase in the inflammatory response and a decrease in quality of life of CD patients. These differences in cytokine levels were not related to CD antibodies status suggesting that IBS, in CD, is related to a different inflammatory process than that which is relevant to CD.

RESUMEN Antecedentes: la evidencia indica que la inflamación de bajo grado puede alterar la función motora y sensorial gastrointestinal y puede contribuir a la aparición de síntomas en el SII. Objetivo: Examinar la relación entre SII, anticuerpos contra enfermedades y títulos de citocinas en pacientes celíacos y un grupo de control. Materiales y métodos: se determinaron los síntomas de SII, actividad de CD y niveles séricos de IL-6, IL-8 e IL12 / 23p40 en pacientes celíacos y controles. Resultados: se incluyeron 123 pacientes celíacos, el 89% eran mujeres. El 59% demostró actividad de la enfermedad y el 32% cumplió con los criterios del SII. La prevalencia del SII no fue diferente entre los pacientes que se adhirieron o no se adhirieron a GFD, así como entre los pacientes con o sin anticuerpos positivos. Los pacientes celíacos tenían niveles aumentados de IL-6, IL-8 e IL12 / 23p40 en comparación con los controles. Se encontraron niveles más altos de citocinas en pacientes celíacos con SII que en aquellos sin SII. No se encontraron diferencias en los niveles de citocinas entre pacientes con y sin anticuerpos CD positivos. Se encontró una correlación negativa significativa entre el componente mental de la calidad de vida y los niveles de IL-6 e IL12 / 23p40, pero no con IL-8. Conclusión: Se encontraron niveles más altos de citocinas inflamatorias en pacientes con EC con SII que en aquellos sin SII o controles, lo que indica que los síntomas del SII están asociados con un aumento en la respuesta inflamatoria y una disminución en la calidad de vida de los pacientes con CD. Estas diferencias en los niveles de citocinas no estaban relacionadas con el estado de los anticuerpos contra la CD, lo que sugiere que el SII, en la CD, está relacionado con un proceso inflamatorio diferente al que es relevante para la CD.

A genetically engineered Fc-binding amphiphilic polypeptide for congregating antibodies in vivo.

We report herein an affinity-based hydrogel used in creating subcutaneous depots of antibodies in vivo. The biomaterials design centered on pG_EAK, a polypeptide we designed and expressed in E. coli. The sequence consists of a truncated protein G (pG) genetically fused with repeats of the amphiphilic sequence AEAEAKAK ("EAK"). Capture of IgG was demonstrated in vitro in gels prepared from admixing pG_EAK and EAK ("pG_EAK/EAK gel"). The binding affinities and kinetics of pG for IgG were recapitulated in the pG_EAK polypeptide. Injecting IgG antibodies formulated with pG_EAK/EAK gel into subcutaneous space resulted in retention of the antibodies at the site for at least six days, whereas only signal at background levels was detected in grafts injected with IgG formulated in saline or diffusion-driven gel. The local retention of IgG in pG_EAK/EAK gel was correlated with limited distribution of the antibody in liver, spleen and lymph nodes, in contrast to those injected with antibodies formulated in saline or non-Fc binding EAK gel. In addition, antibodies formulated with pG_EAK/EAK gel and injected in mouse footpads were found to retain at the site for 19 days. As a demonstration of potential bioengineering applications, thymic epithelial cells (TECs), the primary population of thymic stromal cells that are critical for the development of T-lymphocytes, were mixed with pG_EAK/EAK gel formulated with TEC-specific anti-EpCAM antibodies and injected subcutaneously into athymic nude mice. The injected TECs congregated into functional thymic units in vivo, supporting the development of both CD4+ and CD8+ T cells as well as Foxp3+ regulatory T cells in the mice. In conclusion, pG_EAK/EAK gel can be used to retain IgG locally in vivo, and can be tailored as scaffolds for controlling deposition of molecular and/or cellular therapeutics. STATEMENT OF SIGNIFICANCE: The unique concept of the work centers on the genetic fusion of an Fc-binding domain and a self-assembling domain into a single polypeptide. To our knowledge, such bi-functional peptide has not been reported in the literature. The impact of the work lies in the ability to display IgG antibodies and Fc-fusion proteins of any specificity. The data shown demonstrate the platform can be used to localize IgG in vivo, and can be tailored for controlling deposition of primary thymic epithelial cells (TECs). The results support a biomaterials-based strategy by which TECs can be delivered as functional units to support T-lymphocyte development in vivo. The platform described in the study may serve as an important tool for immune engineering.

Cáncer de cuello uterino, estrategias innovadoras en la descentralización del conocimiento y su manejo. Proyecto ECHO Uruguay / Cervical cancer, innovative strategies in the decentralization of knowledge and its management. ECHO Uruguay Project

El Proyecto ECHO (Extension of Community Health Outcomes) es una iniciativa de alcance internacional cuyo ánimo fue mejorar el acceso a la atención especializada para las poblaciones rurales mediante la utilización de tecnologías de la comunicación. Desde el año 2014 se introdujo en Uruguay, abordando actualmente varias patologías. La Clínica Ginecotocológica A de la Facultad de Medicina desarrolla las teleclínicas ECHO para el abordaje de la prevención y el tratamiento del cáncer de cuello uterino (CCU) en Uruguay de forma mensual desde junio del 2015 hasta la fecha. El objetivo de este trabajo es mostrar los resultados del Proyecto ECHO en Uruguay en el abordaje preventivo del CCU. Entre junio de 2015 y julio de 2016 se realizaron un total de 13 teleclínicas sobre CCU. Se conectaron profesionales desde seis departamentos del país: Paysandú, Rivera, Tacuarembó, San José, Colonia y Montevideo. Los centros asistenciales que se conectaron fueron nueve. Se abordaron 21 casos clínicos, dando respuesta a las interrogantes planteadas y realizándose actualizaciones de temas relevantes sobre la patología. Participan especialistas de diferentes áreas: ginecólogos clínicos, ginecólogos especialistas en tracto genital, anatomopatólogos, imagenólogo, oncólogos, radioterapeutas y residentes de ginecotocología. El promedio de participantes por teleclínica en este período fue de 15. En el abordaje del CCU el proyecto ha brindado la posibilidad de homogeneizar criterios diagnósticos además de la actualización mantenida en todos los aspectos de la enfermedad.

ECHO (Extension of Community Health Outcomes) Project is a global initiative which aims to improve access of rural populations to specialized health care service, by means of using communication technologies. It was introduced in Uruguay in 2014 and it has addressed several conditions already. The Gynecotological Clinic A of the School of Medicine has developed ECHO Tele-Clinics to address prevention and treatment of cervical cancer in Uruguay on a monthly basis, since June 2015 and until today. The study aims to present the results obtained in Project ECHO in Uruguay in the prevention of cervical cancer. 13 Tele-Clinics on cervical cancer were developed from June 2015 until July 2016. Professionals of six departments around Uruguay - Paysandú, Rivera, Tacuarembó, San José, Colonia and Montevideo - participated of them, and 9 healthcare centers took part of the initiative. 21 clinical cases were discussed, answers were provided for the queries submitted and an update on relevant aspects of the condition was given. The Tele-Clinics involved specialists in different areas: clinical gynecologists, gynecologists specialized in the genital tract, pathologists, imagenology specialists, oncologists, radiotherapists, and gynecology residents. Average number of participants was 15. The Project has enabled the homogenization of diagnostic criteria as well as a sustained update on all aspects of the disease in the handling of cervical cancer.

O Projeto ECHO (Extension of Community Health Outcomes) é uma iniciativa com alcance internacional, cujo objetivo é melhorar o acesso à atenção especializada para as populações rurais utilizando tecnologias de comunicação. Foi introduzido no Uruguai em 2014 e atualmente inclui várias patologias. A Clínica Ginecotocológica A da Facultad de Medicina realiza teleclínicas ECHO para a abordagem da prevenção e tratamento do câncer de colo do útero (CCU) no Uruguai mensalmente desde junho de 2015. O objetivo deste trabalho é mostrar os resultados do Projeto ECHO no Uruguai na abordagem preventiva do CCU. Entre junho de 2015 e julho de 2016 foram realizadas 13 teleclínicas sobre CCU. Profissionais de seis departamentos do país: Paysandú, Rivera, Tacuarembó, San José, Colônia e Montevidéu e nove centros assistenciais estiveram conectados. Foram discutidos 21 casos clínicos, respondendo às dúvidas apresentadas e também atualizando temas relacionados a essa patologia. Participaram especialistas de diferentes áreas: ginecologistas clínicos, ginecologistas especializados em sistema genital, patologistas, oncologistas, especialistas em imagens e em radioterapia e residentes de tocoginecologia. O número medio de participantes por teleclínica foi 15. Na abordagem do CCU, o Projeto oferece a possibilidade de homogeneizar critérios diagnósticos além do realizar uma atualização permanente em todos os aspectos da enfermidade.

An optimized clarithromycin-free 14-day triple therapy for Helicobacter pylori eradication achieves high cure rates in Uruguay.

BACKGROUND: Strong acid inhibition increases cure rates with triple therapy and 14-day are more effective than 7-day treatments. The combination of amoxicillin plus metronidazole at full doses has been shown to overcome metronidazole resistance and to achieve good eradication rates even in patients harboring resistant strains. No previous studies have been reported in Latin-America with this optimized triple-therapy scheme. AIMS: The aim of the present study was to assess the eradication rate and tolerance of a new first-line treatment regimen associating strong acid inhibition, amoxicillin and metronidazole. METHODS: Patients from the Clínica de Gastroenterología of the Hospital de Clínicas (Montevideo, Uruguay) were included. Hp status was mainly assessed by at least one of the following: histologyor urea breath test (UBT). A 14-day treatment was prescribed comprising esomeprazole 40mg twice a day plus amoxicillin 1g and metronidazole 500mg, both three times a day. H. pylori cure was assessed by UBT. RESULTS: Forty-one patients were enrolled. Mean age was 53.3±13 years and 17.1% of patients were male. Main indications for treatment were: functional dyspepsia (27.5%), gastritis (45%), gastric or duodenal erosions (20%), gastric ulcer (5%) and intestinal metaplasia (2.5%). H. pylori eradication was achieved in 33 of the 37 patients who returned for follow-up. Eradication rates were 80.5% (95% CI: 68.4-92.6) by intention-to-treat (ITT) analysis and 89.2% (95% CI; 79.2-99.2) per protocol (PP). No major side effects were reported; 26 patients (65.8%) complained of mild side effects (nausea, diarrhea and headache). CONCLUSIONS: Cure rates of this triple therapy including esomeprazole, amoxicillin and metronidazole were 81% per ITT and the treatment was well tolerated. These optimal results with a simple clarithromycin-free triple therapy are better than described for standard triple therapy but there is still room for improvement to reach the desired target of 90% per ITT.

The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus.

The availability of over-the-counter (OTC) proton pump inhibitors (PPIs) for the short-term (2 weeks) management of frequent heartburn (≥2 days/week) has increased markedly, yet evidence-based recommendations have not been developed. A panel of nine international experts in gastroesophageal reflux disease developed consensus statements regarding the risks and benefits of OTC PPIs using a modified Delphi process. Consensus (based on ≥80% approval) was reached through multiple rounds of remote voting and a final round of live voting. To identify relevant data, the available literature was searched and summarized. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system terminology was used to rate the quality of evidence and strength of recommendations; consensus was based on ≥2/3 agreement. After 4 rounds of review, consensus was achieved for 18 statements. Notably, the available data did not directly reflect OTC use, but instead, prescription use; therefore, extrapolations to the OTC setting were often necessary. This limitation is regrettable, but it justifies performing this exercise to provide evidence-based expert opinion on a widely used class of drugs. The panel determined that using OTC PPIs according to label instructions is unlikely to mask the symptoms of esophageal or gastric cancer or adversely impact the natural history of related precursor conditions. OTC PPIs are not expected to substantially affect micronutrient absorption or bone mineral density or cause community-acquired pneumonia, Clostridium difficile infection, or cardiovascular adverse events. However, OTC PPI use may be associated with slightly increased risks for infectious diarrhea, certain idiosyncratic reactions, and cirrhosis-related spontaneous bacterial peritonitis. The available evidence does not suggest that OTC PPI use consistent with label instructions is associated with substantial health risks. To minimize potential risks, healthcare professionals and consumers must actively participate in decision making when managing reflux-related symptoms in the self-care setting.

Pacientes que no responden a prueba con inhibidores de la bomba de protones: diagnóstico y manejo / Patients with symptoms refractory to proton pump inhibitors: diagnosis and management

One third of patients with symptoms of gastro-esophageal reflux disease (GERD) are unresponsive to proton-pump inhibitors (PPIs). Most of them suffer from functional heartburn or other functional pathology. The mechanisms involved include non-acid reflux, aerophagia and belching, reflux hypersensitivity and psychological comorbidities. After ensuring adherence to nonpharmacologic measures and changes in types of PPIs, the initial diagnostic strategy is based on finding erosive esophagitis and rule out eosinophilic esophagitis in endoscopy and prove or rule out abnormal gastro esophageal reflux (GER) and association of symptoms by pH monitoring with or without impedanciometry. After ruling out GERD, the association of symptoms in these tests can direct therapy toward the use of baclofen or pain modulators.

Un tercio de los pacientes con síntomas de enfermedad por reflujo gastro-esofágico (ERGE) no responden a inhibidores de la bomba de protones (IBP). La mayoría de ellos padece una patología esofágica funcional. Los mecanismos implicados incluyen reflujo no ácido, aerofagia y eructos, hipersensibilidad al ácido y comorbilidad psicológica. Luego de asegurar adherencia a medidas no farmacológicas y cambios en tipos de IBP, la estrategia diagnóstica inicial se basa en hallazgo de esofagitis erosiva y descarte de esofagitis eosinofílica en la endoscopia, así como objetivar/descartar RGE patológico y asociación de síntomas mediante pHmetría con o sin impedanciometría. Tras descartar RGE patológico, la asociación de síntomas en estas últimas pruebas pueden dirigir la terapia hacia el uso de baclofeno y moduladores del dolor.

Trombosis de senos venosos intracraneales: una complicación infrecuente y grave de la colitis ulcerosa. Primera comunicación de un caso en Uruguay / Intracranial sinus venous thrombosis in ulcerative colitis: Report of one case

Intracranial sinus venous thrombosis (ICSVT) is a rare complication of ulcerative colitis that affects from 1.7 to 7.5% of patients. We report a 22 year-old male with ulcerative colitis in treatment with mesalazine and prednisone presenting with headache and speech disturbances. A magnetic resonance imaging of the brain showed a left temporal hemorrhagic infarct with thrombosis of the ispilateral superficial vein and sigmoid venous sinus. No cause of thrombophilia was detected. Anticoagulation with heparin was started which was changed to oral anticoagulation with warfarin. The patient was discharged ten days after admission.

[Evolution of the response to the first-line therapy for Helicobacter pylori infection in Uruguay]. / Evolución de la respuesta al tratamiento de primera línea de la infección por Helicobacter pylori en Uruguay.

INTRODUCTION: The eradication rate of the Helicobacter pylori (H pylori) infection using standard triple therapy has dropped globally in recent years, primarily due to the occurrence of antibiotic resistance. METHODS: Several therapy regimens were assessed in 823 patients treated the first time for H pylori infection in Uruguay, during the 1997 to 2011 period, divided into five-year groups. All patients underwent 13C isotope-urea breath testing, between the 8th and 24th weeks after therapy. The standard triple plan (amoxicillin, clarithromycin and proton pump inhibitors) was the most commonly used (86.8%). RESULTS: The overall eradication rate was 66.6% (548 patients). With the standard triple plan, the reported eradication rates were 75% for the first 5-year term and 70.1% for the second 5-year term. The difference between these two periods was not statistically significant (P = 0.201). However, in the last term the eradication rate further declined to 62.4%, with a statistically significant difference (P = 0.014). No significant correlations were found between the response to therapy in this population and either the use of alcohol and/or yerba mate or the smoking habits. CONCLUSIONS: In Uruguay, the eradication rate of H pylori infection has dropped in the last five years and is below the internationally accepted levels. This feature demands searching for more effective alternative therapies, adapting the management to the national reality based on local antibiotic resistance patterns and drug availability.

Radiation exposure in gastroenterology: improving patient and staff protection.

Medical imaging involving the use of ionizing radiation has brought enormous benefits to society and patients. In the past several decades, exposure to medical radiation has increased markedly, driven primarily by the use of computed tomography. Ionizing radiation has been linked to carcinogenesis. Whether low-dose medical radiation exposure will result in the development of malignancy is uncertain. This paper reviews the current evidence for such risk, and aims to inform the gastroenterologist of dosages of radiation associated with commonly ordered procedures and diagnostic tests in clinical practice. The use of medical radiation must always be justified and must enable patients to be exposed at the lowest reasonable dose. Recommendations provided herein for minimizing radiation exposure are based on currently available evidence and Working Party expert consensus.

Management of early-stage esophageal neoplasia (MESEN) consensus.

BACKGROUND: Treatment of esophageal adenocarcinoma often involves surgical resection. Newer technologies in interventional endoscopy have led to a substantial paradigm shift in the management of early-stage neoplasia in Barrett's esophagus comprising high-grade dysplasia (HGD), intramucosal carcinoma, and, in some cases, submucosal carcinoma. However, there has been no consensus regarding the indications for esophageal preservation in these cases. In this work, consensus guidelines were established for the management of early-stage esophageal neoplasia considering clinically relevant aspects (age, comorbidities, and social environment) in each scenario. METHODS: Seventeen experts were invited to participate based on their background and clinical expertise at high-volume centers. A questionnaire was created that included four clinical scenarios covering a wide range of situations within HGD and/or early esophageal neoplasia, particularly where controversies are likely to exist. Each of the clinical scenarios was open to discussion subdivided by patient age (20, 50, and 80 s). For each clinical scenario an expert was chosen to defend that position. Each defense triggered a subsequent discussion during a consensus meeting. Conclusions of that discussion together with an accompanying literature analysis allowed experts to confirm or change their original choices and served as the basis for the recommendations stated in this article. RESULTS: There was 100 % consensus supporting esophageal preservation in patients with HGD, independent of patient age or Barrett's length. In patients with T1a adenocarcinoma, consensus for preservation was not reached (65 %) for young and middle-aged individuals but was supported for elderly patients (100 %). For T1b adenocarcinoma, consensus was reached for surgical resection (90 %), leaving organ preservation for patients with very low risk of nodal invasion or poor surgical candidates. CONCLUSION: Advances in endoscopic imaging and therapy allow for organ preservation in most settings of early-stage neoplasia of the esophagus, provided that the patient understands the implications of this decision.

Evolución de la respuesta al tratamiento de primera línea de la infección por Helicobacter pylori en Uruguay / [Evolution of the response to the first-line therapy for Helicobacter pylori infection in Uruguay].

INTRODUCTION: The eradication rate of the Helicobacter pylori (H pylori) infection using standard triple therapy has dropped globally in recent years, primarily due to the occurrence of antibiotic resistance. METHODS: Several therapy regimens were assessed in 823 patients treated the first time for H pylori infection in Uruguay, during the 1997 to 2011 period, divided into five-year groups. All patients underwent 13C isotope-urea breath testing, between the 8th and 24th weeks after therapy. The standard triple plan (amoxicillin, clarithromycin and proton pump inhibitors) was the most commonly used (86.8

(548 patients). With the standard triple plan, the reported eradication rates were 75

for the first 5-year term and 70.1

for the second 5-year term. The difference between these two periods was not statistically significant (P = 0.201). However, in the last term the eradication rate further declined to 62.4

, with a statistically significant difference (P = 0.014). No significant correlations were found between the response to therapy in this population and either the use of alcohol and/or yerba mate or the smoking habits. CONCLUSIONS: In Uruguay, the eradication rate of H pylori infection has dropped in the last five years and is below the internationally accepted levels. This feature demands searching for more effective alternative therapies, adapting the management to the national reality based on local antibiotic resistance patterns and drug availability.

Gastric endoscopic submucosal dissection: from animal model to patient.

AIM: To assess whether the use of porcine models is useful for learning endoscopic submucosal dissection (ESD), thus contributing to its subsequent application in human patients. METHODS: This study/learning process was carried out in 3 phases: Phase I: Ex vivo animal; Phase II: In vivo animal; Phase III: Humans. One endoscopist performed 30 gastric ESDs in porcine models, and later 5 gastric ESDs in 5 patients. The ESD was done following the method practiced at the National Cancer Center in Tokyo, Japan. Technical aspects, size, time and speed of ESD, as well as complications were registered. In patients, their clinical, endoscopic and histologic evolution was additionally added. RESULTS: Thirty en bloc ESDs were carried out in animal models. The mean ± SD size of the pieces was of 28.4 ± 1.2 mm, and the time of ESD was 41.7 ± 2.4 min. The time of ESD in the first 15 procedures was 43.0 ± 3.0 min whereas in the next 15 procedures, the time was 40.3 ± 3.9 min, P = 0.588. The speed in the first 15 ESDs was 1.25 ± 0.11 cm(2)/min vs 2.12 ± 0.36 cm(2)/min in the remaining 15, P = 0.028. There were no complications. In patients, 5 lesions were resected en bloc. The size of the pieces was 25.2 ± 5.1 mm and the time was 85.0 ± 25.6 min. Endoscopic and histological controls did not show evidence of residual neoplastic tissue. CONCLUSION: A sequential ESD training program of a unique endoscopist, based on the practice in porcine models, contributed to learning ESD for its subsequent application in humans, yielding good results in efficacy and safety.

La Organización Mundial de Gastroenterología y sus realizaciones en América Latina / The world gastroenterology organization and its achievements in Latin America

La Organización Mundial de Gastroenterología (OMGE; World Gastroenterology Organization, WGO) es una federación de más de 100 sociedades nacionales y 4 asociaciones regionales de gastroenterología que representan a 50 000 individuos. La OMGE se enfoca a promover el conocimiento del público y profesionales de la salud sobre la prevalencia mundial de las enfermedades digestivas y a alcanzar programas de educación y entrenamiento de alta calidad, accesible e independiente, especialmente para el mundo en desarrollo. Las iniciativas educativas de la OMGE incluyen hasta el momento: 15 centros de entrenamiento; 21 cursos de Train the Trainers para docentes; un programa de Outreach que facilita el suministro de equipos y accesorios; el Día Mundial de la Salud Digestiva; 24 guías globales con su metodología de cascada que las hace únicas en su género, y el Congreso Mundial de Gastroenterología. La Fundación de la OMGE es el recurso filantrópico que le permite recaudar los fondos necesarios para estas actividades. En este artículo se hace hincapié en las principales actividades desarrolladas en los últimos 10 años en América Latina.

The World Gastroenterology Organization is a federation of more than 100 national societies and 4 regional associations of gastroenterology that represent more than 50,000 physicians. The WGO is focused in the promotion of the knowledge of the people and the physicians about the world prevalence of digestive disorders and reach programs of education and training of high quality, independent and of easy access, especially for the developing world. This WGO programs include until this moment: 15 training centers; 21 courses of "train the trainers" for professors , an Outreach program that facilitates the supplies of equipment and its accessories, the World Day in Digestive Health; 24 global guidelines with the cascade methodology that make them unique and the World Congress of Gastroenterology. The WGO foundation is the philanthropic resource that allows having funds for these activities. In this article we make foothold in the principal activities developed in the last 10 years for Latin-America.

[Barrett's esophagus: an update]. / Esófago de Barrett: actualización del tema.

Barrett's esophagus is an acquired condition that results in a serious injury of the esophageal mucosa and whose importance lies in the possible progression to esophageal adenocarcinoma. The incidence of esophageal adenocarcinoma continues to rise in the Western world, being survival rate very grim when diagnosis is made in later stages. For this reason the current strategies to improve survival in patients with esophageal adenocarcinoma focus on cancer detection at an early and potentially curable stage. This purpose could be achieved either by screening patients most likely to have Barrett's esophagus or by endoscopic surveillance in patients with known Barrett's esophagus. However, the detection and monitoring strategies are currently invasive, expensive and with not really proven benefit. However, new techniques have been and are developed to improve the diagnosis and treatment in order to change the current reality. The aim of this paper is to update the reader on this pathology in terms of pathophysiological and epidemiological aspects, but especially in relation to advances in diagnosis and endoscopic treatment. We also propose a guideline for monitoring and clinical management in this group of patients.

Diversity of VacA intermediate region among Helicobacter pylori strains from several regions of the world.

Helicobacter pylori is known to be a major cause of gastric carcinoma and peptic ulceration. cagA positivity and vacA's signal regions and mid-regions are well-characterized markers of H. pylori's virulence. Recently, an intermediate region has been identified as another strong marker of H. pylori-associated disease, and its i1 allele has been linked with severe diseases in colonized hosts. The goal of this study was to determine the prevalence of the intermediate alleles in H. pylori isolates from China, Turkey, and Uruguay and from U.S. Africans and to compare their distribution with other well-characterized virulence factors. Originally, 123 H. pylori strains were studied, but 3 were excluded due to the failure to amplify the intermediate region in these samples. Therefore, a total of 120 strains were analyzed: 30 Chinese isolates, 35 Turkish isolates, 30 Uruguayan isolates, and 25 U.S. African isolates. The s type and the m type were determined by PCR amplification. The i type was identified by PCR amplification and DNA sequencing. CagA status was determined by PCR methodology. There was a strong correlation among CagA positivity, s1, and i1 in Chinese, U.S. African, and Uruguayan isolates, but less correlation among these markers in Turkish isolates. A new intermediate variant (i3) was identified in 25.7% of Turkish strains and 3.3% of the Chinese strains. In summary, the distribution of CagA positivity and s1 correlated with the i1 in the three populations, except in the Turkish population, which showed a disproportionate representation of the i3 allele. Phylogenetic mapping confirmed the i-typing method previously defined and adopted for this study. The phylogenetic tree showed country-specific correlation with the intermediate region. Our results showed that the i1 allele is strongly associated with CagA positivity and the vacA s1 allele, suggesting its role as a virulence marker and potential predictor for clinical outcome.